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Abstract
Background—Interpersonal communication is inherent in a majority of strategies seeking to 
engage prescriber and pharmacist health care professionals (HCPs) in the reduction and prevention 
of prescription drug abuse (PDA). However, research on HCP PDA communication behavioral 
engagement and factors that influence it is limited.
Objectives—This study quantitatively examined communication behaviors and trait-level 
communication metrics, and qualitatively described prescription drug abuse-related 
communication perceptions and behaviors among primary care prescribers and community 
pharmacists.
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Methods—Five focus groups (N=35) were conducted within the Appalachian Research Network 
(AppNET), a rural primary care practice-based research network (PBRN) in South Central 
Appalachia between February and October, 2014. Focus groups were structured around the 
administration of three previously validated trait-level communication survey instruments, and one 
instrument developed by the investigators to gauge HCP prescription drug abuse communication 
engagement and perceived communication importance. Using a grounded theory approach, focus 
group themes were inductively derived and coded independently by study investigators. Member-
checking interviews were conducted to validate derived themes.
Results—Respondents’ trait-level communication self-perceptions indicated low communication 
apprehension, high self-perceived communication competence, and average willingness to 
communicate as compared to instrument specific criteria and norms. Significant variation in HCP 
communication behavior engagement was noted specific to PDA. Two overarching themes were 
noted for HCP-patient communication: 1) influencers of HCP communication and prescribing/
dispensing behaviors, and 2) communication behaviors. Multiple sub-themes were identified 
within each theme. Similarities were noted in perceptions and behaviors across both prescribers 
and pharmacists.
Conclusions—Despite the perceived importance of engaging in PDA communication, HCPs 
reported that prescription drug abuse communication is uncomfortable, variable, multifactorial, 
and often avoided. The themes that emerged from this analysis support the utility of 
communication science and health behavior theories to better understand and improve PDA 
communication behaviors of both prescribers and pharmacists, and thereby improve engagement 
in PDA prevention and treatment.
Keywords
Communication; Prescriber; Pharmacist; Prescription Drug Abuse; Qualitative
INTRODUCTION
Prescription drug abuse, considered the United State’s (US) fastest growing drug problem, 
has been associated with significant morbidity and mortality in recent decades.1,2 Deaths 
related to prescription opioid analgesic (POA) overdoses have quadrupled in the US since 
1999.2 Since 2009, the number of POAs dispensed by US retail pharmacies has consistently 
exceeded 200 million.3 POA abuse and addiction are potential adverse effects associated 
with prescription opioids, and are noted public health concerns in the US.
Specific to health care providers, national and state-level efforts to reduce prescription drug 
abuse and the ramifications thereof have included increased education about appropriate 
POA prescribing and dispensing, increased sharing and use of data between state 
prescription drug monitoring programs, increased emphasis on appropriate and timely 
medication disposal, increased screening for drug abuse, and increased access to addiction 
treatment.1,4 Many of the aforementioned efforts have been targeted at front-line health care 
providers such as POA prescribers and community pharmacists. Significant research has 
been conducted to examine prescribers’ and pharmacists’ perceptions and behaviors related 
to prescription drug monitoring programs5–12 and general attitudes toward prescription drug 
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abuse and interventions that could mitigate it.13–18 Overall, research suggests providers 
perceive prescription drug abuse to be a problem in their practice settings and 
communities;16,17,19 moreover, providers express support for interventions that could reduce 
prescription drug abuse.10,13–15,20
Interpersonal communication is inherent in a majority of strategies seeking to engage health 
care professionals in the reduction and prevention of prescription drug abuse. However, 
research exploring provider communication behaviors specific to prescription drug abuse is 
limited.20–22 To better understand behavioral engagement in prescription drug abuse-related 
communication, the research team performed five focus groups with prescribers and 
pharmacists in South Central Appalachia who were actively engaged in POA prescribing and 
dispensing. One goal of the focus groups was to inform adaptation of McCroskey et al’s 
trait-level communication apprehension,23 self-perceived communication competence,24 and 
willingness to communicate25 assessments to situational prescription drug abuse-specific 
communication and evaluate behavioral engagement across multiple situations (see details 
below). The objectives of this manuscript are: 1) to quantitatively describe communication 
behaviors and trait-level communication metrics in our study sample; and 2) to qualitatively 
describe prescription drug abuse-related communication perceptions and behaviors of 
prescribers and pharmacists with patients.
METHODS
Participants and Focus Groups
Employing a qualitative study design, the investigators conducted five focus groups within 
the Appalachian Research Network (AppNET), a rural primary care practice-based research 
network (PBRN) in South Central Appalachia, between February and October, 2014.26,27 
Focus groups consisted of two prescriber-specific groups, two pharmacist-specific groups, 
and one interprofessional (prescribers and pharmacists) group. The location of each focus 
group varied. Two were conducted at participants’ practice settings, one at a geographically 
centralized practice setting at which none of the participants practiced, another at a 
conference attended by primary care providers and pharmacists, and one at a centrally-
located academic institution.
Prescriber focus groups were purposively sampled to include all active primary care 
providers (PCPs) and clinic directors within a particular clinic. Pharmacist focus groups 
were purposively sampled to include community pharmacists practicing within similar 
geographical areas (i.e., within the same communities). The interprofessional focus group 
purposively included both prescribers and pharmacists attending the annual AppNET 
conference. Researchers distributed and reviewed the informed consent document and 
confidentiality requirements prior to obtaining written consent from participants and before 
beginning each focus group. Participants were compensated for their time with a modest 
honorarium. A total of 35 prescribers and pharmacists participated in the focus groups 
(median=6/group; range=6–9). The investigators used a semi-structured interview guide 
(Appendix) designed to facilitate group discussion around communication issues between 
prescribers, pharmacists, and patients regarding prescription drug abuse. All focus groups 
were moderated by a minimum of two study authors (NH, FT, AH). Focus groups were 
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approximately 60–80 minutes in duration. All focus groups were audiotaped and transcribed 
verbatim. The investigators and research assistants took field notes during each focus group.
Survey Instruments
Focus groups were structured around the administration of four brief survey instruments; 
three developed by McCroskey and colleagues to evaluate perceptions of communication 
apprehension, self-perceived communication competence, and willingness to communicate, 
and one instrument developed by the investigators to gauge prescription drug abuse 
communication engagement. The Personal Report of Communication Apprehension 
(PRCA-24) was used to assess trait-level communication apprehension.23 The PRCA-24 
allows calculation of aggregate communication apprehension scores as well as group, 
interpersonal, meeting, and public speaking domain scores. Higher scores on the PRCA-24 
indicate increased apprehensiveness when communicating. The Self-Perceived 
Communication Competence (SPCC) Questionnaire was administered to assess 
communication competence.24 Both aggregate and sub-domain (e.g., acquaintance, dyad, 
friend, group, meeting, public speaking, stranger) scores were calculated. Higher SPCC 
scores indicate increased perceptions of communication competence. Respondent 
willingness to communicate was assessed using the Willingness to Communicate (WTC) 
Scale.25 Aggregate and sub-domain WTC scores were calculated in the same way SPCC 
scores were calculated. Higher WTC scores indicate increased willingness to communicate 
across multiple situations. Overall, each of the instruments assesses trait-level 
communication perceptions across multiple audiences, ranging from close friends to groups 
of strangers, and contexts, ranging from interpersonal communication to public speaking.
The prescription drug abuse communication behavior instrument evaluated the extent of 
engagement in nine prescription drug abuse prevention/treatment behaviors and the 
perceived importance of engaging in each behavior. Using a 0–10 scale, focus group 
participants were asked to estimate the frequency (e.g., X out of 10 times that I have this 
opportunity I have this conversation) of engagement in prescription drug abuse conversations 
with their patients. All of the behaviors included in the investigator-developed instrument 
were based on nationally recognized prevention/treatment strategies.1,4 The 4 
aforementioned survey instruments facilitated discussions during the interviews of how best 
to transform trait-like survey instruments into prescription drug abuse-specific instruments 
and the role of communication in addressing prescription drug abuse with patients and other 
providers.
Data Analysis
PRCA-24, SPCC, and WTC scores and sub-scores were calculated for all focus group 
participants. Scores were calculated based on standardized scoring procedures for each 
instrument.23–25,28 Descriptive statistics were calculated for participant prescription drug 
abuse-related behaviors and communication survey assessment scores.
Using a grounded theory approach, focus group themes were inductively derived and coded 
independently by two of the study investigators (NH, FT).27,29 Emerging themes were 
iteratively refined throughout the course of the focus group conduction. Saturation was 
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achieved by the fourth focus group. A third investigator (RP) was available to resolve 
discrepancies in coding. Major themes and sub-themes were finalized, and the quotes that 
most accurately illustrated the themes (exemplar quotes) were identified. Validation of the 
data was achieved by conducting member-checking interviews30 with five participants from 
the focus groups after compilation of the final draft of themes. Themes were then refined 
based on member-checking interviews.
Approval was obtained from X University’s Institutional Review Board prior to study 
conduction.
RESULTS
Demographic characteristics of the study sample are presented in Table 1. The study sample 
was approximately evenly divided across gender and prescriber/pharmacist categories. 
Descriptive statistics for prescription drug abuse communication behaviors and 
communication scores are presented in Tables 2 and 3, respectively. Health care 
professionals most often engaged in discussing the results of a prescription drug monitoring 
program query, concerns regarding a patient’s drug-taking behaviors, and the abuse potential 
of prescribed medications. All communicative behaviors were considered by a majority of 
study participants to be extremely important conversations in which to engage patients. 
Respondents’ overall PRCA-24, SPCC, and WTC scores indicated relatively low 
communication apprehension, relatively high self-perceived communication competence, 
and average willingness to communicate when compared to instrument specific criteria and 
norms.28 Respondents indicated their lowest level of communication apprehension in 
interpersonal communication scenarios. Similarly the highest level of communication 
competence was noted in the dyadic communication domain. Willingness to communicate 
was highest when communicating with a friend and lowest when communicating with a 
stranger. Reflective of prescription drug abuse provider-patient communication contexts, 
dyadic and interpersonal communication sub-scores revealed average communication 
apprehension, communication competence, and willingness to communicate scores. 
Approximately 15% of focus group participants reported high apprehension, low 
communication competence, and low willingness to communicate.
Two overarching themes were noted for health care professional (HCP – both prescribers 
and pharmacists)-patient communication: 1) influencers of HCP communication and 
prescribing/dispensing behaviors; and 2) communication behaviors. Sub-themes were 
identified within each theme, are described below, and are presented in Table 4.
Influencers of HCP Communication and Prescribing/Dispensing Behaviors
Seven sub-themes were identified within the influencers of HCP communication and 
prescribing/dispensing behaviors theme: 1) subjective vs. objective patient information; 2) 
practice setting barriers; 3) patient relationships; 4) level of HCP training and experience; 5) 
pharmacists’ lack of patient information; 6) fear of patient responses; 7) individual and 
practice setting policies.
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Subjective vs. objective patient information—Both prescribers and pharmacists 
commented often that the subjectivity inherent in pain management and prescription drug 
abuse and addiction influenced their communicative and prescribing/dispensing behaviors. 
HCPs emphasized the weight of relatively objective factors, “hard evidence”, or “red flags” 
when determining their patient care and communication approaches. Commonly cited hard 
evidence included urine drug screen results, results of prescription drug monitoring program 
(PDMP) queries, distance travelled to a clinic/pharmacy, and patient age.
One physician said, “If you’ve got someone with a drug screen that’s positive, it’s a pretty 
easy discussion because you can…almost technicalize that without having to…be 
judgmental, whereas if you just notice weird behaviors, that’s a little hard to deal with.” 
Similarly, a pharmacist said, “If it’s someone who, you look at the database (PDMP) and 
they’ve seen multiple physicians, and gotten multiple scripts, then you want to confront 
them about it and ask them about it, and you want to notify the prescriber who wrote the 
current prescription.”
HCPs highlighted the distinction between evidence and suspicion of prescription drug abuse. 
One pharmacist noted, “I suspect a lot of patients have [prescription drug abuse] problems, 
but only a few I can prove.” A physician noted, “When you look [at the PDMP] and they’ve 
got prescriptions somewhere they weren’t supposed to or they failed their drug test then I 
can say ‘Look, it’s not just my gestalt that you’re pulling one over, but I’ve got proof.’”
Regarding the subjectivity inherent in the treatment of pain and the detection of abuse, one 
nurse practitioner stated, “There’s so much of pain that’s subjective.” Prior to 
communicating with a patient about a prescription drug abuse concern, HCPs 
overwhelmingly preferred to have proof of abuse. It was seldom explored as part of routine 
patient care. One physician said, “You have to have some degree of belief that that’s [abuse] 
going on.” The fear of undertreating legitimate pain was also mentioned: “I think one thing 
that does make me a little bit worried or apprehensive…if I do make a mistake and I thought 
it was drug seeking and it really wasn’t, and they perhaps had pain beyond a level that I 
appreciated…and perhaps their life at home really was that painful and things. I hope that 
I’m pretty good at not missing those truly in pain.” When considering the subjective nature 
of prescription drug abuse, HCPs also mentioned the possibility of getting duped by patients. 
A nurse practitioner said, “You want do the right thing for the patient but at the same time 
you don’t want to be taken advantage of and be doing the wrong thing.”
Practice setting barriers—Prescribers and pharmacists commonly indicated practice 
time constraints as a barrier to engaging patients in prescription drug abuse communication. 
A nurse practitioner explained, “You’re given 15–20 minutes per patient so when you’re 
looking at controlled substances on top of hypertension and diabetes…it becomes 
problematic in trying to address everything you’re suppose to.” A pharmacist said, “I 
worked nine hours by myself and filled 300 prescriptions. I didn’t get a lunch break and I 
didn’t get a bathroom break. I don’t know how anyone is going to have time [to engage 
patients in prescription drug abuse communication] when you are expected to work under 
the normal circumstances like that. If I really care about patients, I want to do it correctly. 
And if we can’t do it well then we don’t want to do it at all.”
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HCPs highlighted the relationship between perceived time constraints and financial 
consequences. A physician noted, “If you took time to do all of this [engage in prescription 
drug abuse communication]…you’d be broke is another way of saying it.” Another 
physician stated, “In terms of referring them to [addiction] treatment centers, actually that’s 
much more time consuming to me than just to say ‘look you failed, you’re fired.’ And we’re 
not paid for it either.” Both prescribers and pharmacists noted the business aspects of their 
prescribing and dispensing behaviors. The perception that physicians meet specific patient 
load requirements, and the financial ramifications of not doing so, was mentioned. One 
prescriber said, “I mean, you’ve got to make a number. You’ve got to stay busy.” A 
community pharmacist owner said, “It’s an interesting paradigm…we have the least amount 
of reimbursement that we’ve ever had. Cash flow is an issue with everybody. And then you 
get someone who comes in with a prescription that is $1000 cash, and all of a sudden we are 
the bad guy for filling it, because we fill something that we shouldn’t.”
Prescribers, in particular, noted the impact of addressing prescription drug abuse with 
patients on clinic, institutional and/or personal metrics, such as patient satisfaction ratings 
and meaningful use scores. A nurse practitioner noted, “I have heard conversations in the 
past of providers fearing losing scores by not fulfilling the patients’ desires, by not giving 
them what they need, as far as medication goes because she did…she went and wrote a 
formal complaint against me and that’s a ding against me. When really I was looking out for 
her.” A physician similarly noted, “There’s all these benchmarks, and we want high scores 
so we’re trying to make sure we get that. We all agree that this [prescription drug abuse] is a 
difficult problem but trying to find that time to do it [communicate] is a challenge.”
Regarding a lack of resources, a physician said, “In my area I don’t think we even have 
anyone as far as [addiction] treatment is concerned.” A nurse practitioner noted, “We don’t 
have good resources to send somebody who probably is addicted, or abusing. What do you 
do with them?” Similarly, a pharmacist stated, “He was the one who asked for a 
recommendation for a place to go to around here. I said, ‘All we know are the pill mills.’ We 
don’t want him to go to one of those places.” Variation was also noted as to what was 
considered a resource:
NH: What types of prescription drug abuse information and addiction treatment 
information do you have in your clinic that you can give to patients?
MD1: We haven’t got anything do we?
MD2: We’ve got a social worker.”
Those providers that indicated they do have some resources in their clinics indicated barriers 
to providing timely information. A physician noted, “We do have a list of places and phone 
numbers where they can go in for substance abuse treatment…but it’s hard to keep all of that 
updated.”
Patient relationships—Pharmacists and prescribers indicated that the depth of the HCP-
patient relationship could impact engagement in prescription drug abuse communication. 
Some HCPs noted that communication is more likely with established patients. A nurse 
practitioner said, “I feel like with an established patient I can say, ‘now come on…why are 
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you still on this or what’s going on? Tell me for real.’” Conversely, another nurse 
practitioner said, “I think it’s easier to be strong when it’s a new patient. It’s a different story 
when it’s someone you’ve seen for months or even years and then it’s an issue. Because 
you’ve got some history with the patient.” A pharmacist said, “I work in a town that I was 
born in. You want to keep up just a good positive relationship with them so this is very 
negative to bring up, so that’s difficult and knowing that I will continue to see the same 
patients over and over again. There will be awkwardness.”
Level of HCP training and experience—Prescribers, in particular, highlighted the role 
of their training and experience level in decisions to address abuse and addiction. A nurse 
practitioner noted, “Am I trained in pain management? About as well as any other primary 
care provider is.” Physicians described the entry into practice post-residency as critical in 
establishing an approach to handling pain management and prescription drug abuse 
concerns. One physician said, “When I was the new guy, my schedule was packed with all 
the druggies. Everybody came in just wanting Lortab™ and Xanax™.” Two experienced 
physicians conversed, MD1: “I think it’s much easier having some experience as a physician 
too. It’s much easier now than it was right after I got out of training. Probably one because 
of experience and two because I’ve got a full practice and I really don’t care if I make you 
mad and if you leave because it’s not going to hurt me financially. Whereas if your 
schedule’s not full then you’re more apt to…MD2: “give all the pain medication you want.”
Pharmacists’ lack of patient information—Community pharmacists perceived 
difficulty in engaging in communication based on a lack of accessible patient information 
that could inform their communication approaches. One pharmacist said, “I don’t know 
enough about you to know if this is a safe dose for you. What kind of pain? What is being 
treated? I think you [pharmacists] are entitled to know more than that. And you have to 
know more than that.” Another pharmacist commented, “I think what’s getting lost in the 
shuffle is knowledge about the patient.” Another pharmacist said: “Get access to medical 
records. That would answer so many questions.” Pharmacists also commented on their 
reliance on the PDMP and the challenges of accessing the required data quickly. “You know, 
I’ve got a patient waiting for me to make a decision and…I can’t even look at the database 
[PDMP]. I can’t say come back in an hour, I’m going to be closed in an hour. You know…
what do you do with that?”
Fear of patient responses—Fear of patient response caused apprehension in the 
decision to communicate specific to prescription drug abuse, as well as the decision to 
prescribe or dispense controlled substances. One pharmacist said, “We have become cynical, 
and you can communicate all you want to, but we have become cynical, and kind of afraid.” 
Another noted, “Some patients are scary that are abusing drugs and those I just sort of…I 
legitimately fill [the prescription]. I don’t do anything illegal, but I’m thinking, they’re just 
going to go out here and sell this.” A physician described the dissonance between fear of 
certain patients and professional responsibility, “I feel intimidated when I’m in the room 
with [one patient]…she has never been aggressive, never talked to me in an abusive fashion 
but she comes off as a very aggressive person. And so I do feel intimidated when I’m with 
her, but I’m not going to back down because I’m accountable for what I do.” Prescribers also 
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mentioned differences in fear perceptions across patient gender. One conversation went as 
follows:
“MD1 (male): It’s a lot easier to have a conversation with females that fail [a drug 
screen or PDMP query] for me than the men, and I think the primary reason is 
because men…you just worry they’re going to get violent and explode.
MD2 (female): See I think I’m the opposite. I think I’d rather have a conversation 
with a male.
MD1: Really.
MD2: Maybe it’s because I don’t like all the females to cry on me you know…
MD1: I just never…I never read about the females pulling out a hand gun and 
blowing away half the clinic and stuff.”
Individual and practice setting policies—Prescribers and pharmacists routinely 
described individual and setting-specific policies that are employed to guide communication 
and prescribing and dispensing behaviors. Policies included establishment of setting-specific 
maximum patient capacities, development of pain/addiction treatment contracts, and 
establishment of inclusion and exclusion criteria based on patient or prescriber 
characteristics. Whereas the techniques differed across prescribers and dispensers, the 
concepts were similar. Regarding maximum patient capacities, one pharmacist mentioned, 
“Right now we have an established patient load of about 25–30 patients [on Suboxone™ for 
the treatment of addiction]. And we are not taking any new ones on Suboxone™.” One nurse 
practitioner stated the following in regards to maximum patient capacities, “The most 
appealing thing about coming to this office was the fact that our policy is we do not 
prescribe controlled substances…but in hindsight coming aboard and taking on patients that 
other prescribers have seen in the past that have had controlled substances prescribed to 
them by other prescribers and having to continue doing that…well it’s a reality check for 
me. Trying to hold to the standard of not prescribing to those patients has been very, very 
challenging.”
Regarding policy development, one pharmacist noted, “I actually made a Suboxone™ 
contract…wrote it up and all of our patients have to sign a contract.” Other pharmacists 
mentioned employing “all or none” policies that require patients to get all of their 
prescription medications, controlled and non-controlled substances, filled at one pharmacy. 
Physicians employed individual policies to direct their practice behaviors, including 
development of stepwise processes for prescribing and patient discharge from practices. One 
physician said, “You like to think what we’re trying to do is help these people fix their 
problems and some people, I mean, to be quite honest, it’s just not pleasant to deal with. I 
mean, I just discharge you and I’m done. That’s awful to say but it’s true.” Similarly, 
another physician conversation went as follows:
“MD1: Usually they’ll fail the drug screen or the prescriber database and that takes 
care of it. We discharge from the practice. Now the one thing I don’t think we do is 
say ‘Hey here are some treatment centers’, do we?”
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MD2: No we don’t
MD1: We probably ought to say here’s some options…”
MD2: Here’s some options for treatment. We just…I don’t know.
MD3: But you’re too ticked off at them.”
Communication Approaches and Behaviors
Prescribers and pharmacists employed multiple approaches to communicate with patients 
about prescription drug abuse: 1) standard operating conversations; 2) consequential 
communication; and 3) communication avoidance.
Standard operating conversations—Prescribers, in particular, mentioned employing 
standard operating conversations. One physician said, “I’ll be direct and I’ll say well you 
know ‘I don’t know you. I don’t prescribe these medications on the first visit. If I see you for 
a couple times and think you need them I might prescribe them but there’s a good chance I 
might not.’” A nurse practitioner noted, “I have had patients who got up and walked out of 
the room when I go in because the nurse will tell them ahead of time that we don’t prescribe 
narcotics and they’re here for back pain and that I’m not going to give them narcotics. I go 
in and I confirm that it’s not going to happen…I expect my management to back me up on 
that, because that’s the right thing to do.”
One pharmacist, when uncomfortable with a dispensing scenario employed a standard safety 
conversation with patients. The pharmacist stated, “[I’ll say] ‘I don’t know who you are, I 
don’t know this doctor. I can’t get ahold of them to figure out what you’ve been on, so forth 
and so on, and I can’t fill this because I don’t feel like this is a safe dose for you at this point 
in time.’ In the end, that’s my go-to. It’s just not safe.”
Consequential communication—Some HCPs employed consequential conversations to 
promote prescription drug abuse prevention and gather patient information. A physician 
stated, “I do it [discuss medication storage] with almost every patient, I say, ‘Do you have a 
lock box or a safe? If any of this stuff gets stolen then you’re going to be in deep problems 
concerning your pain and withdrawal.’ So I’m telling them to keep it locked up…they know 
if it gets lost or stolen not to call me for an early refill.” When exploring prescription drug 
abuse, one pharmacist said, “If I come across one [PDMP report] that says they skipped 
February [didn’t have a prescription filled during February], I know there’s a problem and 
I’ll ask them ‘Where did you get this filled last time? This isn’t going to be filled until you 
tell me. It will be a whole lot quicker if you just go ahead and tell me where you got this 
filled because then I can call and get the date [of the last fill].’ And usually they just go 
ahead and tell me because they don’t want to sit there all day.” Similarly, a physician 
described, “When we suspect this [abuse] and they do fall out [fail] on some parameter 
[urine drug screen or PDMP query], we let them know that they’ve fallen out, that we are 
concerned, and we quit prescribing for them and then we discharge them from the practice. 
And that’s sort of the end of it.” Related to consequential communication, contractual 
communication was also employed, particularly by prescribers. One prescriber said, “We 
have this form and it’s got three copies to it…And I say, ‘Now remember, you can never 
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increase the number, and you can never increase the strength.’ It’s a small percent of the 
patients we see a day, but for us it’s the part that we stress ourselves with. That, and maybe 
somebody dying.”
Communication avoidance—Both prescribers and pharmacists commonly engaged in 
communication avoidance behaviors and conversations with patients. The approaches 
enabled providers to avoid difficult or confrontational situations. A pharmacist explained, “I 
think personally I would just rather go with the flow than confront issues like that; it’s 
definitely harder to confront.” Some pharmacists mentioned lying to patients to avoid 
perceivably difficult conversations. One pharmacist said, “I just tell them I don’t have them 
[prescribed medications].” Prescribers mentioned placing communicative responsibility on 
practice staff. A physician noted, “We have somebody who makes our new patient 
appointments and who tells people upfront we don’t prescribe medications unless for 
legitimate reasons.” When discussing abuse detection activities, another physician said, “Oh 
gosh I hate this, my nurse does all that. I tell her and she can do it [call a patient to come to 
the office for an unannounced pill count] on her own if she wants.”
Some physicians referred patients to other providers to avoid difficult cases. A physician 
said, “I mean if I think someone’s abusing something and I’ve got some sort of proof or 
strong feeling they are, I don’t have a problem telling them that. I’ll just tell them ‘I think 
this is a problem and I’m not going to write your pain medications anymore. I can refer you 
to a pain clinic.’” Likewise, pharmacists mentioned referring patients back to their 
prescribers to explore medication-taking behaviors. A pharmacist explained, “If it’s a 
situation of, you know, a patient coming back 15 days after a 30 day fill wanting it filled and 
you discuss that with them as far as, ‘Hey you know, you’re taking more than prescribed, 
you might want to talk to your doctor about if it’s not adequate or if you’re needing more 
medication.’ I don’t ever accuse anybody of abuse of drugs or anything like that.”
Prescribers also mentioned avoiding communication related to exploration of patients’ 
illnesses. One prescriber noted, “I think to say ‘No’ [to prescribing a controlled substance to 
a patient] as compared to saying ‘Hey I think you’re hooked.’ It’s one thing to say no. It’s 
another thing to address the root problem. And somebody that’s going to become 
argumentative and stuff I’m going to just say no and not really address the root problem…I 
may just choose to fire you versus trying to help you with your problem.”
DISCUSSION
This study is the first to describe prescription drug abuse (PDA)-related communication 
perceptions and behaviors of prescribers and pharmacists with patients. Few respondents 
reported trait-level communication perceptions that could hinder overall communication 
engagement. Yet, despite the perceived importance of engaging in PDA communication, 
respondents reported that prescription drug abuse communication is uncomfortable, variable, 
multifactorial, and often avoided. Our findings indicate similarities in perceptions and 
behaviors across both prescribers and pharmacists. Overall, multiple factors are considered 
by providers when choosing to engage in PDA communication, and multiple approaches, are 
employed to minimize real and perceived difficult conversations.
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While communication apprehension, competence, and willingness were infrequently 
mentioned verbatim by focus group participants, the sub-themes that presented in the 
analysis align with the aforementioned constructs. Fear of patient responses, a lack of 
objective evidence of abuse, and fear of damaging patient relationships, for example, 
indicate potentially elevated situational apprehension. Respondents indicated feeling more 
confident in their ability to communicate with increased training or experience and the 
presence of “hard” evidence. Similarly, practice setting barriers, a lack of objective evidence, 
a lack of pharmacist information, fear of damaging patient relationships, and fear of a 
patient’s response to communication all decrease one’s willingness to communicate in PDA 
situations.
The PDA-related behaviors reported by prescribers and pharmacists indicate that PDA-
related communication avoidance is common. Importantly, highly apprehensive situations, 
either real or perceived, predict communication avoidance.31 Whereas the trait-level 
communication instruments employed in this study did not capture widespread 
communication apprehension or other communication factors that indicate prescribers and 
pharmacist may avoid communication, the state-level questions asked in the focus groups 
revealed routine engagement in communication avoidance behaviors. To date, state-level 
communicative analyses in health care settings have been primarily limited to the 
perspective of the patient.32–34 These studies indicated communication apprehension and 
avoidance interfere with provider-patient relationships and are associated with negative 
patient outcomes.34 The results of our qualitative analysis support that apprehension and 
communication avoidance often result in PDA conversations that are not patient-centered 
(e.g., lying to patients, firing patients, failing to recommend patients for treatment when 
appropriate), or in no conversations at all.
Interventions to improve communication skills and correct communication perceptions of 
health care professionals are approaches to improving PDA prevention and treatment given 
that communication is inherent in these strategies. McCroskey and colleagues pointed out 
that interventions developed to decrease situational communication apprehension and 
avoidance have two potential targets: improving situational communication skills (i.e., a 
behavioral emphasis) and decreasing situational apprehension (i.e., a cognitive emphasis).35 
Considering our prescribers and pharmacists, improving patient-centered communication 
skills through motivational interviewing-based training, for example, could decrease 
communication avoidance in those individuals who lack communication skills. Ideally, skills 
would be externally evaluated, in addition to a self-assessment. Similarly, interventions such 
as systematic desensitization have been shown to decrease communication apprehension in 
health professions students.36 Importantly, interventions need to be targeted to the needs of 
the communicators. Attempting to reduce apprehension in a provider who has low or 
appropriate situational communication apprehension would be ineffective if communication 
skills are the limiting factor in PDA communication engagement.
Additional avoidance behaviors were influenced by factors that could be considered outside 
the realm of communication science. Time and financial pressures are two examples. 
Incorporation of additional behavior theories, such as the theory of planned behavior could 
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also inform provider willingness to engage in PDA prevention and treatment efforts and 
interventions to positively impact these efforts.37
Limitations
The geographic specificity of this study in Northeast Tennessee and the limited sample size 
limit the generalizability of the perceptions to other prescribers and pharmacists. Only 
perspectives or prescribers and pharmacists were gathered in this study. Patients’ perceptions 
would further inform our work and future research in this area.
Conclusion
To the authors’ best knowledge, this is the first study to examine situational communication 
perceptions specific to prescription drug abuse. Prescribers and pharmacists reported 
multiple factors that influence their engagement in PDA communication. Prescribers and 
pharmacists also indicated communication is important, yet variable in its frequency, quality, 
and intent. The themes that emerged from this analysis support the utility of communication 
science and health behavior theories to better understand and improve PDA communication 
behaviors of both prescribers and pharmacists, and thereby improve engagement in PDA 
prevention and treatment. The results of this qualitative study can inform future quantitative 
studies of HCP-patient communication with regard to PDA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix. Questions Comprising the Semi-Structured Interview Guide
Communication Behavior Instrument Questions
• What other behaviors do you engage in related to prescription drug abuse 
that are not included in the questionnaire?
• What factors do you consider when deciding whether or not to engage in 
the behaviors included in the questionnaire?
• What factors do you consider when determining the legitimacy of a 
patient’s need for drugs with abuse/addiction potential?
• What is the typical plan of action when you encounter a patient you 
perceive to be abusing prescription drugs?
• What is the typical plan of action when you encounter a patient you 
perceive to be addicted to prescription drugs?
• What concluding thoughts to you have about we can best capture 
prescription drug abuse communication behaviors in this short 
questionnaire?
Self-Perceived Communication Competence Instrument Questions
• How would you describe your confidence in your ability to speak with 
your patients about prescription drug abuse concerns?
– What types of situations make you feel confident?
– What types of situations make you feel unconfident?
• If we desire to transform this short questionnaire into a survey that 
measures your confidence specific to prescription drug abuse 
communication, what factors do we need to consider?
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Personal Report of Communication Apprehension – PRCA 24 Instrument 
Questions
• Almost all, if not all of us, have some situations in which we feel anxious 
or apprehensive when talking to one or more people. With which type of 
audience would you say your apprehension is the highest? In what context 
would you say your apprehension is the highest?
• If we desire to transform this short questionnaire into a survey that 
measures your apprehension specific to prescription drug abuse 
communication, what factors do we need to consider?
Willingness to Communicate Scale Questions
• Now consider this instrument specific to prescription drug abuse 
communication. Describe factors that influence whether or not you choose 
to engage in communication with your patients.
• Think of a time when you probably should have engaged a patient in a 
conversation about prescription drug abuse or an addiction, but chose not 
to do so
– Describe the situation
– What factors played a role in your decision not to 
communicate with this patient?
• If we desire to transform this short questionnaire into a survey that 
measures your willingness to communicate specific to prescription drug 
abuse communication, what additional factors do we need to consider?
Concluding Questions
• What types of prescription drug abuse information do you have available 
for patients in your practice setting?
• What resource(s) do you think would positively influence the extent to 
which you engage in PDA/M communication with your patients?
– Reimbursement?
– Training?
– Time?
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ARTICLE SYNOPSIS
This manuscript describes a qualitative study of primary care prescribers and community 
pharmacists that explores prescription drug abuse-related communication with patients. 
Two major themes and multiple sub-themes emerged, including employment of 
individual and practice specific policies and conversations, practice setting barriers, and 
fear of patient response. Despite the perceived importance of engaging in prescription 
drug abuse communication, providers reported that prescription drug abuse 
communication is uncomfortable, variable, multifactorial, and often avoided. Emerging 
themes inform development of interventions that can improve engagement of prescribers 
and pharmacists in prescription drug abuse prevention and treatment.
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Highlights
• Communication is inherent in prescription drug abuse (PDA) 
prevention and treatment
• Provider communication behaviors are variable specific to PDA
• PDA communication is uncomfortable, multifactorial, and often 
avoided
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Table 1
Focus Group Participant Demographic Characteristics (N=35).
Variable Category Number (%)
Age
31–40 12 (34)
41–50 9 (26)
51+ 14 (40)
Gender
Female 17 (49)
Male 18 (51)
Profession
Administrator 1(3)
Nurse Practitioner 5 (14)
Pharmacist 16 (46)
Physician 13 (37)
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Table 2
Prescription Drug Abuse-Related Communicative Behaviors and Perceived Importance of Behavioral 
Engagement.
Behaviora Mean (SD) Range Median Importance Ratingb
Discuss abuse potential of prescribed medications 6.6 (2.0) 4–10 3
Discuss appropriate storage of drugs with abuse potential 4.7 (2.9) 0–10 3
Explore personal histories of drug abuse 5.7 (3.4) 0–10 3
Conduct a drug abuse risk assessment or screening 5.1 (3.7) 0–10 3
Verbally refer a patient for drug abuse treatment 3.5 (3.7) 0–10 3
Discuss the results of a prescription drug monitoring program query 7.3 (2.9) 0–10 3
Discuss your concern with a patient regarding his/her drug-taking behaviors 6.7 (2.7) 2–10 3
Discuss your concern with a prescriber regarding his/her prescribing behaviors 3.0 (2.6) 0–10 3
Discuss your concern with a pharmacist regarding his/her dispensing behaviors 3.0 (3.0) 0–8 3
aOn a scale from 0 to 10, please estimate the frequency with which you engage in prescription drug abuse conversations with your patients or 
health care professionals when the opportunity presents;
bOn a scale of 1 to 3, how important do you feel it is to engage in conversations with your patients or health care professionals regarding each of 
the aforementioned items
Res Social Adm Pharm. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hagemeier et al. Page 21
Table 3
Personal Report of Communication Apprehension-24, Self-Perceived Communication Competence, and 
Willingness to Communicate Scores.
Construct Mean (SD) Range Possible Score Range
PRCA-24-Group 14.9 (6.4) 6–26 6–30
PRCA-24-Meetings 14.6 (6.3) 6–27 6–30
PRCA-24-Interpersonal 14.4 (5.4) 6–27 6–30
PRCA-24-Public Speaking 17.5 (7.0) 6–30 6–30
PRCA-24-Total 61.4 (22.8) 24–97 24–120
SPCC-Acquaintance 83.9 (16.2) 45–100 0–100
SPCC-Dyad 92.0 (9.4) 67–100 0–100
SPCC-Friend 85.2 (14.8) 40–100 0–100
SPCC-Group 84.7 (17.2) 27–100 0–100
SPCC-Meeting 75.8 (23.6) 20–100 0–100
SPCC-Public Speaking 77.2 (23.1) 23–100 0–100
SPCC-Stranger 74.8 (24.3) 20–100 0–100
SPCC-Total 81.3 (18.0) 35–100 0–100
WTC-Acquaintance 71.1 (19.9) 35–100 0–100
WTC-Friend 79.7 (12.2) 60–100 0–100
WTC-Group 70.6 (14.8) 45–100 0–100
WTC-Interpersonal 73.7 (17.3) 40–100 0–100
WTC-Meeting 62.1 (22.1) 30–100 0–100
WTC-Public Speaking 59.7(19.7) 22–100 0–100
WTC-Stranger 48.8 (22.0) 14–94 0–100
WTC-Total 66.5 (15.7) 39–98 0–100
PRCA-24: Personal Report of Communication Apprehension; SPCC: Self-Perceived Communication Competence Questionnaire; WTC: 
Willingness to Communicate Scale
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Table 4
Emerging Themes as Determinants of Prescription Drug Abuse Communication.
Influencers of HCP Communication and Prescribing/Dispensing Behaviors
• Subjective vs. objective patient information
• Practice setting barriers
• Patient relationships
• Level of HCP training and experience
• Pharmacists’ lack of patient information
• Fear of patient responses
• Individual and practice setting policies.
Communicative Approaches and Behaviors
• Standard operating conversations
• Consequential communication
• Communication avoidance
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